Heightened response of eosinophilic asthmatic patients to the <scp>CRTH</scp>2 antagonist <scp>OC</scp>000459

OC000459 is a safe and effective oral anti-inflammatory agent, which achieved clinically meaningful improvements in lung function and asthma control in allergic asthmatics with an eosinophil-dominant form of the disease. A dose of 25 mg given once daily was as effective as the higher doses studied.